Display options
Cite
Gupta VB, Doecke JD, Hone E, et al. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst). 2015;3:18-26doi: 10.1016/j.dadm.2015.12.001.
Gupta, V. B., Doecke, J. D., Hone, E., Pedrini, S., Laws, S. M., Thambisetty, M., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D., Masters, C. L., Macaulay, S. L., Rembach, A., Rainey-Smith, S. R., Martins, R. N. (2016). Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimer's & dementia (Amsterdam, Netherlands), 318-26. https://doi.org/10.1016/j.dadm.2015.12.001
Gupta, Veer Bala, et al. "Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 3 (2016): 18-26. doi: https://doi.org/10.1016/j.dadm.2015.12.001
Gupta VB, Doecke JD, Hone E, Pedrini S, Laws SM, Thambisetty M, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Macaulay SL, Rembach A, Rainey-Smith SR, Martins RN. Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging. Alzheimers Dement (Amst). 2015 Dec 22;3:18-26. doi: 10.1016/j.dadm.2015.12.001. eCollection 2016. PMID: 27239546; PMCID: PMC4879652.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2015 Dec 22;3:18-26. doi: 10.1016/j.dadm.2015.12.001. eCollection 2016.

Plasma apolipoprotein J as a potential biomarker for Alzheimer's disease: Australian Imaging, Biomarkers and Lifestyle study of aging.

Alzheimer's & dementia (Amsterdam, Netherlands)

Veer Bala Gupta, James D Doecke, Eugene Hone, Steve Pedrini, Simon M Laws, Madhav Thambisetty, Ashley I Bush, Christopher C Rowe, Victor L Villemagne, David Ames, Colin L Masters, Stuart Lance Macaulay, Alan Rembach, Stephanie R Rainey-Smith, Ralph N Martins,

Affiliations

  1. School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia; Cooperative Research Centre for Mental Health, Melbourne, Australia.
  2. CSIRO Health and Biosecurity, Brisbane, Australia.
  3. Unit of Clinical and Translational Neuroscience Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
  4. Cooperative Research Centre for Mental Health, Melbourne, Australia; Oxidation Biology Unit, The Florey Institute, The University of Melbourne, Melbourne, Australia.
  5. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia.
  6. National Ageing Research Institute, Parkville, Australia; Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Australia.
  7. Oxidation Biology Unit, The Florey Institute, The University of Melbourne, Melbourne, Australia.
  8. CSIRO Food and Nutrition Flagship, Parkville, Australia.
  9. School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.
  10. School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia; Cooperative Research Centre for Mental Health, Melbourne, Australia; School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, Australia.

PMID: 27239546 PMCID: PMC4879652 DOI: 10.1016/j.dadm.2015.12.001

Abstract

INTRODUCTION: For early detection of Alzheimer's disease (AD), the field needs biomarkers that can be used to detect disease status with high sensitivity and specificity. Apolipoprotein J (ApoJ, also known as clusterin) has long been associated with AD pathogenesis through various pathways. The aim of this study was to investigate the potential of plasma apoJ as a blood biomarker for AD.

METHODS: Using the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, the present study assayed plasma apoJ levels over baseline and 18 months in 833 individuals. Plasma ApoJ levels were analyzed with respect to clinical classification, age, gender, apolipoprotein E (APOE) ε4 allele status, mini-mental state examination score, plasma amyloid beta (Aβ), neocortical Aβ burden (as measured by Pittsburgh compound B-positron emission tomography), and total adjusted hippocampus volume.

RESULTS: ApoJ was significantly higher in both mild cognitive impairment (MCI) and AD groups as compared with healthy controls (HC; P < .0001). ApoJ significantly correlated with both "standardized uptake value ratio" (SUVR) and hippocampus volume and weakly correlated with the plasma Aβ1-42/Aβ1-40 ratio. Plasma apoJ predicted both MCI and AD from HC with greater than 80% accuracy for AD and greater than 75% accuracy for MCI at both baseline and 18-month time points.

DISCUSSION: Mean apoJ levels were significantly higher in both MCI and AD groups. ApoJ was able to differentiate between HC with high SUVR and HC with low SUVR via APOE ε4 allele status, indicating that it may be included in a biomarker panel to identify AD before the onset of clinical symptoms.

Keywords: Apolipoprotein J; Biomarkers; Brain amyloid beta; Hippocampus volume; Plasma

References

  1. JAMA. 2011 Apr 6;305(13):1322-6 - PubMed
  2. Neurology. 2011 Mar 22;76(12 ):1091-8 - PubMed
  3. Neurology. 1988 Mar;38(3):359-64 - PubMed
  4. Neuroimage. 2012 Jan 2;59(1):212-7 - PubMed
  5. PLoS One. 2012;7(11):e50237 - PubMed
  6. Brain. 2007 Nov;130(Pt 11):2837-44 - PubMed
  7. Nat Med. 2004 Jul;10 Suppl:S34-41 - PubMed
  8. Neuron. 1990 Dec;5(6):831-9 - PubMed
  9. Exp Neurol. 1995 Nov;136(1):22-31 - PubMed
  10. J Alzheimers Dis. 2011;25(3):421-4 - PubMed
  11. J Lipid Res. 1990 Mar;31(3):545-8 - PubMed
  12. J Proteome Res. 2011 Apr 1;10(4):2006-10 - PubMed
  13. Arch Gen Psychiatry. 2010 Jul;67(7):739-48 - PubMed
  14. Int Psychogeriatr. 2009 Aug;21(4):672-87 - PubMed
  15. Mol Biosyst. 2008 Jan;4(1):42-52 - PubMed
  16. Nat Genet. 2009 Oct;41(10):1094-9 - PubMed
  17. Arch Neurol. 2005 May;62(5):770-3 - PubMed
  18. Exp Neurol. 1998 Dec;154(2):511-21 - PubMed
  19. JAMA. 2010 May 12;303(18):1832-40 - PubMed
  20. Curr Alzheimer Res. 2013 Nov;10 (9):973-8 - PubMed
  21. FASEB J. 2007 Aug;21(10):2312-22 - PubMed
  22. Mol Psychiatry. 2014 Jan;19(1):88-98 - PubMed
  23. EMBO Rep. 2005 Dec;6(12):1131-6 - PubMed

Publication Types